Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

Scientists have discovered a naturally occurring molecule that aids appetite control and weight loss so well, it may compete ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

This long-term agreement will help support the commercialization of VK2735.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...